Tidal Investments LLC Has $4.46 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB

Tidal Investments LLC trimmed its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 11.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 162,384 shares of the company’s stock after selling 21,740 shares during the quarter. Tidal Investments LLC’s holdings in Genmab A/S were worth $4,461,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. SBI Okasan Asset Management Co.Ltd. bought a new position in shares of Genmab A/S in the 4th quarter valued at about $673,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Genmab A/S by 36.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Genmab A/S in the 1st quarter valued at about $1,198,000. Diversify Wealth Management LLC acquired a new stake in Genmab A/S in the 1st quarter valued at about $1,216,000. Finally, First Trust Advisors LP grew its holdings in Genmab A/S by 84.3% during the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after purchasing an additional 1,126,069 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

GMAB opened at $32.47 on Monday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The business has a fifty day simple moving average of $31.00 and a 200 day simple moving average of $28.26. Genmab A/S Sponsored ADR has a 1 year low of $23.62 and a 1 year high of $35.43. The company has a market capitalization of $20.25 billion, a PE ratio of 25.57, a price-to-earnings-growth ratio of 1.83 and a beta of 0.84.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Research analysts expect that Genmab A/S Sponsored ADR will post 1.17 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Truist Financial initiated coverage on Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price objective on the stock. Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. HC Wainwright boosted their target price on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. New Street Research set a $43.00 price target on Genmab A/S in a research note on Wednesday, July 22nd. Finally, Guggenheim raised their price target on Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average target price of $39.50.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.